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Objective: Transrectal ultrasound-guided prostate (TRUS) biopsy is the standard method for the diag-
nosis of prostate cancer. Quinolone-based prophylaxis before a TRUS biopsy of the prostate is the most
common regimen worldwide. In this retrospective study, we evaluated the efﬁcacy and cost effectiveness
of adding gentamicin to a ﬂuoroquinolone-based prophylaxis regimen.
Materials and methods: In total, our study included 263 patients classiﬁed into two groups. Group 1
consisted of 129 patients who received one oral dose of levoﬂoxacin (500 mg) daily 2 days before the
biopsy, on the day of the biopsy, and for 2 days after the biopsy. Group 2 consisted of 134 patients who
received a single intramuscular (IM) gentamicin injection (80 mg) 30 minutes before the biopsy in
addition to the same oral levoﬂoxacin protocol as Group 1. We recorded and analyzed data including age,
indication for a TRUS biopsy of the prostate, prostate volume, comorbidity, infectious complications, and
blood and urine culture results.
Results: The mean prostate-speciﬁc antigen level was 38.6 ng/mL ± 312.9 ng/mL (range, 4.4e2626 ng/
mL) in Group 1, and 34.8 ng/mL ± 127.1 ng/mL (range, 2.11e1423 ng/mL) in Group 2. The groups were
similar in terms of mean age, indication for a biopsy, prostate volume, number of biopsy cores taken, and
comorbidities. Infection-related complications occurred in eight of 129 (6.2%) and in one of 134 (0.74%)
patients in Groups 1 and 2, respectively (p ¼ 0.02).
Conclusion: The addition of IM gentamicin (80 mg) was beneﬁcial in improving the efﬁcacy of ﬂuo-
roquinolone and reducing the post-TRUS biopsy infection rate. Gentamicin is relatively inexpensive and
readily available in daily practice and has good compliance for patient use.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Transrectal ultrasound-guided prostate (TRUS) biopsy is the
standard method for the diagnosis of prostate cancer.1 It is gener-
ally a safe procedure with acceptable complication rates. Infectious
complications after a prostate biopsy include fever, urinary tract
infections, acute bacterial prostatitis, epididymo-orchitis, and
sepsis.2 The reported incidence of urinary tract infections after a
TRUS biopsy typically ranges between 2% and 6%, withung Shan Medical University
Taichung 402, Taiwan, ROC.
ociation. Published by Elsevier Taapproximately 30e50% of these patients exhibiting accompanying
bacteremia.3,4 Bacteremia is frequently accompanied by severe
sepsis, which has a reported overall incidence of 0.1e2.2% following
a TRUS biopsy.3 A Canadian study reported increasing rates of
hospitalization within a 30-day period following a TRUS biopsy,
from1.0% in 1996 to 4.1% in 2005 (p< 0.0001).5 Similarly, using data
derived from Medicare records, researchers from the United States
also reported an increasing frequency of infectious complications
following a TRUS biopsy, increasing from 0.4% in 1991 to 1.1% in
2007 (p < 0.0001).6 Therefore, reducing the postbiopsy infection
rate is a challenge in the TRUS biopsy era.
Fluoroquinolone is one of themost commonly used prophylactic
antibiotics for TRUS biopsies and has been used in our hospital for
the past years. The American Urological Association guidelines foriwan LLC. This is an open access article under the CC BY-NC-ND license (http://
T.-Y. Hsieh et al. / Urological Science 27 (2016) 91e9592the use of prophylactic antibiotics for a TRUS biopsy of the prostate
state that all recommended antibiotics are acceptable in the
outpatient setting.7 Furthermore, Western countries have reported
and recommend aminoglycosides in combination with metroni-
dazole, or ﬂuoroquinolones and cephalosporins for TRUS biopsies.
The incidence of prostate cancer varies from one country to
another, with the highest incidence being found in the Western
world and the lowest in Asian countries.8 Therefore, owing to the
relatively low incidence of prostate cancer, there could be different
views regarding the feasibility and cost effectiveness of such for-
mula used in Asian countries.
In this study, we compared infectious complication rates in
patients undergoing a TRUS biopsy of the prostate who were given
prophylactic levoﬂoxacin only with those given levoﬂoxacin com-
bined with a single dose of intramuscular (IM) gentamicin (80 mg)
to evaluate the efﬁciency of adding IM gentamicin to standard
prophylaxis in reducing infection-related complications after a
TRUS biopsy.2. Materials and methods
We conducted this retrospective study from January 2008 to
August 2011. The charts of patients who received a TRUS biopsy in
this period were reviewed. The patients who did not receive lev-
oﬂoxacin as a prophylactic antibiotic were excluded. Patient's his-
tory was reviewed, including age, diabetes mellitus (fasting plasma
glucose level S 130 mg/dL), hypertension (blood pressure S 140/
90 mmHg), and other comorbidities. In total, the study included
263 patients. Group 1 consisted of 129 patients who received one
oral dose of levoﬂoxacin (500mg) daily 2 days before the biopsy, on
the day of the biopsy, and for 2 days after the biopsy. Group 2
consisted of 134 patients who received a single IM gentamicin in-
jection (80 mg) 30 minutes before the biopsy in addition to the
same oral levoﬂoxacin protocol as Group 1. Whether or not to add
gentamicin as an adjunctive is decided by the attending doctor.
The indications for a TRUS biopsy included elevated prostate-
speciﬁc antigen (PSA) level (>4 ng/mL), abnormal digital rectal
examination, ﬁndings in a ﬁrst prostate biopsy that necessitated a
repeat biopsy such as the presence of an atypical gland or persistent
elevation of PSA.
Almost all of the patients received the TRUS biopsy as an
outpatient procedure except those who came for consultation for
prostate biopsy during admission. Urine analysis, coagulation
proﬁle, and serum creatinine were all examined before the TRUS
biopsy. Bowel movements were ensured with Bisacodyl (Dulcolax)
suppositories given the previous night, and all patients had a
cleansing enema before the procedure. With the patient in the left
decubitus position, the TRUS biopsy was performed by an urologist
with a multiplanar, multifrequency probe (75 MHz) attached to an
ultrasound scanner. The prostate volume was calculated using the
prostate ellipsoid formula: volume (V) ¼ 0.52 (L W  H), where L
is the cephalocaudal diameter, W is the width, and H is the ante-
roposterior diameter. The patients with superhigh PSA levels
demonstrating osteoblast bone metastasis received 10 cores pros-
tate biopsy; all other patients received 12e16 cores biopsy. The
prostate biopsies were taken with an 18-gauge  20-cm needle
with an automated spring loaded gun mechanism (Bard Biopsy
Gun). The biopsies were obtained at the apex, middle, and base of
the bilateral prostate lobes in the parasagittal plane.
The patients were informed to return to the hospital if they
developed a fever (>38.5C), chills, or newly developed severe
lower urinary tract symptoms and macroscopic hematuria with
blood clots. The patients who experienced the aforementioned
symptoms within 14 days of the procedure in the absence of otherclinically apparent sources of infection were deﬁned as having
“post-TRUS biopsy infection-related complications.”
Mean and standard deviations were determined. These two
groups were compared with respect to descriptive characteristics
and factors before and after biopsy using the Chi-square, Fisher
exact test, and the student t test. A p value &0.05 was considered
statistically signiﬁcant.
3. Results
The characteristics of patients in the two groups are listed in
Table 1. They were similar in terms of mean age (68.4 years ± 8.747
years in Group 1 and 69.20 years ± 10.394 years in Group 2),
indication for biopsy, prostate volume (32.65 mL ± 10.82 mL in
Group 1 and 35.46 mL ± 12.35 mL in Group 2), and the number of
biopsy cores taken. The mean PSA level was 38.653 ng/
mL ± 312.9249 ng/mL (range, 4.4e2626 ng/mL) in Group 1, and
34.843 ng/mL ± 127.1309 ng/mL (range, 2.11e1423 ng/mL) in Group
2. The percentage of patients with hypertension and diabetes was
31% (40/129) and 17% (22/129) in Group 1, 34.3% (46/134) and 14.9%
(20/134) in Group 2, respectively. The comorbidities are compara-
ble in both groups.
As shown in Figure 1 and Table 1, infection-related complica-
tions occurred in eight of 129 (6.2%) and one of 134 (0.74%) patients
in Groups 1 and 2, respectively (p ¼ 0.02). Table 2 shows the
possible etiological risk factors (including antibiotic prophylaxis,
diabetes mellitus, hypertension, age, prostate cancer, and biopsy
core number) and predisposing infection-related complications
after a prostate biopsy. There was no statistically signiﬁcant asso-
ciation between comorbidities including diabetes, hypertension,
age, biopsy core number, and the pathology with postbiopsy
infection-related complications, except antibiotics prophylaxis.
The patients with infection-related complications were hospi-
talized for intravenous antibiotics treatment. All organisms isolated
were tested for antibiotic susceptibility to second- and third-
generation cephalosporins as shown in Table 3. Over our study
period, there were four blood cultures and one urine culture that
were positive for Escherichia coli in nine cases of post-TRUS biopsy-
related sepsis. Three of the four positive blood cultures were
resistant to levoﬂoxacin with only one exhibiting sensitivity. Of the
four positive blood cultures, three were sensitive to gentamicin.
4. Discussion
Currently, TRUS biopsy of the prostate remains the most com-
mon procedure for the detection of prostate cancer. Although the
procedure is generally considered to be safe and well-tolerated,
postbiopsy complications are reported in up to 50% of cases,
including pain, hematuria, hematospermia, urinary retention, and
infection.9 Septicemia is the most dangerous complication
following the procedure and requires emergency admission and
administration of intravenous antibiotics. The most common
pathogen implicated in post-TRUS biopsy sepsis is E. coli, account-
ing for approximately 75e90% of infectious complications in pub-
lished series.10 In our ﬂuoroquinolones-only prophylactic group,
infection-related complications occurred in eight of 129 (6.2%)
patients, which was comparable with previous reports.3,4 Our re-
sults indicated that ﬂuoroquinolones were effective as prophylaxis
for TRUS prostate biopsies in 86.6% of patients. E. coli was the only
causative organism identiﬁed in our positive cultures. Over our
study period, there were four positive blood cultures and one
positive urine culture in nine cases of post-TRUS biopsy-related
sepsis. This ﬁnding is consistent with other reports, and thus, we
directed our antibiotic prophylactic treatment at E. coli. Tal et al2
also identiﬁed E. coli as the most common pathogen in their series.
Table 1
Patient characteristics from both groups.
Levo-only group Levo þ GM group p
No. of patients 129 134 N/S
Age (y) 68.4 ± 8.747 69.20 ± 10.394 N/S
PSA (ng/mL) 38.653 ± 112.9249 (4.4e2626) 34.843 ± 127.1309 (2.11e1423) N/S
Total prostate volume (mL) 32.65 ± 10.82 35.46 ± 12.35 N/S
No. of biopsy core 12.4 ± 1.4 12.7 ± 1.6 N/S
DM 22 20 N/S
Hypertension 40 46 N/S
Infection-related complications 8/129 (3.0%) 1/134 (0.4%) 0.02
prostate cancer 29 36 N/S
Levo ¼ levoﬂoxacin; DM ¼ diabetes mellitus; GM ¼ gentamicin; N/S ¼ not signiﬁcant; PSA ¼ prostate-speciﬁc antigen.
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antimicrobial prophylaxis was effective in preventing infectious
complications following a prostate biopsy. Fluoroquinolones, sul-
fonamides, and other classes of antibiotics have been reported to beFigure 1. Bar graph demonstrates the infection related to TRUS prostate biopsy in the
levoﬂoxacin-only and levoﬂoxacin combined with gentamicin groups.
GM ¼ gentamicin; Levo ¼ levoﬂoxacin; TRUS ¼ transrectal ultrasound. *p > 0.05,
**p ¼ 0.02.
Table 2
Prophylaxis and potential risk factors predisposing infectious complications after
prostate biopsy.
Risk factor Total Infection p
No Yes
Prophylaxis 0.02
Levo only 129 (49.0) 121 (46.0) 8 (3.0)
Levo þ GM 134 (51.0) 133 (50.6) 1 (0.4)
Hypertension 0.610
No 177 (67.3) 171 (65.0) 6 (2.3)
Yes 86 (32.7) 83 (31.6) 3 (1.1)
DM 0.538
No 219 (83.3) 211 (80.2) 8 (3.0)
Yes 44 (16.7) 43 (16.3) 1 (0.4)
Pathology 0.074
BPH 198 (75.3) 189 (71.9) 9 (3.4)
CaP 65 (24.7) 65 (24.7) 0 (0)
Age (y) 0.168
<60 43 (16.3) 40 (15.2) 3 (1.1)
S60 220 (83.7) 214 (81.4) 6 (2.3)
No. of biopsy core 0.176
10e12 233 (88.6) 224 (85.2) 9 (3.4)
>12 30 (11.4) 30 (11.4) 0 (0)
Data presented as numbers, with percentages in parentheses.
BPH ¼ benign prostatic hyperplasia; CaP ¼ prostate carcinoma; DM ¼ diabetes
mellitus; GM ¼ gentamicin; Levo ¼ levoﬂoxacin.effective comparedwith a placebo; however, most reports favor the
use of ﬂuoroquinolones.11 Nevertheless, ﬂuoroquinolone-resistant
E. coli isolates were found to have increased in the past decades.
Our results also showed the high incidence (three fourth) of
ﬂuoroquinolone-resistant E. coli isolated from post-TRUS biopsy
infection cases, which is consistent with the report by Feliciano
et al.12 The rates of resistant E. coli isolates in the United States were
reported to be 0% in 1998 and 12% in 2007, whereas in the United
Kingdom, the reported rates were 1% in 1994 and 23% in 2006.13 In
pursuit of ideal antibiotic prophylactic treatment, various regimens
have been used with no clear consensus among urologists. Rodri-
guez and Terris14 used IM gentamicin if the patient had valvular
heart disease.14 Ho et al15 also reported that the addition of IM
gentamicin was effective in improving the efﬁcacy of levoﬂoxacin
in reducing the incidence of sepsis. Our results also support the fact
that the addition of gentamicin is beneﬁcial in reducing the post-
TRUS biopsy infection-related complication rate. Targeted therapy
of prophylaxis as opposed to empirical prophylaxis had been re-
ported in recent years. The targeted prophylactic antibiotics used
before prostate biopsy were based on the sensitivity of bacteria
isolated from rectal swabs of each patient. Such regimens were
demonstrated to be highly efﬁcacious in reducing infection
complication after prostate biopsy.16 A disadvantage of targeted
therapy is that it is expensive and time consuming compared with
our regimen.Table 3
Microbiologic characteristics of the isolates and susceptibility of antibiotics.
Patient 1 2 3 4 5 6 7 8 9
Urine culture N N N N N N N N P
Urine microorganism E. coli
Blood culture N N N N P N P P P
Blood microorganism E. coli E. coli E. coli E. coli
Antibiotic sensitivity
Ampicillin R R S I
Amoxicillin/clavulanic R R S S
Piperacillin S S S S
Cefazolin R S S S
Ceftazidime S S S S
Ceftriaxone S S S S
Cefepime S S S S
Ciproﬂoxacin R R S R
Levoﬂoxacin R R S R
Imipenem S S S S
Ertapenem S S S S
Meropenem S S S S
Amikacin S S S S
Gentamicin R S S S
Trimethoprim/sulfamethoxazole R R R R
Piperacillin/tazobactam S S S S
E. coli ¼ Escherichia coli; I ¼ intermediate; N ¼ negative; P ¼ positive; R ¼ resistant;
S ¼ susceptible.
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and procedural factors that may predict which men are at greatest
risk of infectious complications.6,12,14 The risk factors identiﬁed are
underlying medical comorbidities, particularly diabetes mellitus,
hypertension, recent hospitalization, and number of biopsy cores.
Our study does not conﬁrm the association between comorbidities
and biopsy infection-related complication. Although one study
found that an increased number of cores taken during the biopsy
procedurewas associatedwith postbiopsy infection,17 other studies
have not conﬁrmed this association.10,18,19 Our data also demon-
strates that those with increased biopsy cores have no statistically
signiﬁcant higher postbiopsy infection-related complication rates.
In addition to efﬁcacy in preventing infections, the cost effec-
tiveness and clinical applicabilities of a regimen should be consid-
ered. In a survey of 900 practicing American urologists, only 3.3%
used a combination of oral and IM prophylactic antibiotics.20 Shi-
gemura et al21 reported that isepamicin plus ﬂuoroquinolone can
be considered a valuable regimen for antibiotic prophylaxis in
TRUS biopsies. Batura et al22 reported that adding amikacin to
ﬂuoroquinolone-based antimicrobial prophylaxis in areaswith high
ﬂuoroquinolone resistance confers signiﬁcant beneﬁts in prevent-
ing infections after a TRUS biopsy.22 A single dose of gentamicin
(80 mg) is relatively cheap (each vial costs US$ 0.15), readily avail-
able, and appropriate for outpatient clinical application. Gentami-
cin's pharmacokinetics suggests that the drug plays a prophylactic
role as well. The 30-minute lag time between IM injection and TRUS
biopsy allows for maximal serum bioavailability at the time of the
procedure, which agrees with the principle of surgical antibiotic
prophylaxis. A recent randomized trial demonstrated that a piper-
acillin/tazobactam (2.25 g) prophylactic regimen for 2 days for TRUS
biopsies of the prostate resulted in a lower incidence of bacteriuria
and febrile urinary tract infections compared with oral ciproﬂoxa-
cin.23 Because of the high cost and patient compliance with piper-
acillin/tazobactam, prophylaxiswith quinolones plus IMgentamicin
in patients undergoing a TRUS biopsy of the prostate seems to be a
better choice and has cost beneﬁts.
However, the increasing rate of aminoglycoside resistance is
another issue in the prevention of post-TRUS biopsy infectious com-
plications, and aminoglycoside resistance is commonly encountered
alongside ﬂuoroquinolone resistance and extended spectrum beta-
lactamase production.24 Awareness of aminoglycoside resistance is
another issue when considering the appropriate choice of empiric
treatment for patients presenting to hospital with post-TRUS biopsy
infections, particularly given that some recent guidelines advocate
aminoglycosides for the empiric treatmentof urosepsis.25 In addition,
due to the renal toxic effects of gentamicin, it is not recommended in
patients with marked renal function impairment.
Our study has several limitations. First, there is uncertainty
regarding patient compliance with the oral intake of prophylactic
antibiotics as prescribed. Second, some of the infectious compli-
cations may not have been related to the prostate biopsy. In addi-
tion, the retrospective nature of the study design and
nonrandomization of the study groups are also limitations.
The European Association of Urology guideline recommended
a single-dose prophylaxis for low-risk patients and a prolonged
course for high-risk patients.25 Despite the relatively high
comorbidities, including diabetes mellitus and hypertension, in
our study groups, our protocol, levoﬂoxacin daily 2 days before
the biopsy, on the day of the biopsy, and for 2 days after the
biopsy, still had room to be adjusted. Further research is war-
ranted to establish the utility and cost effectiveness of adding
gentamicin or other combinations of antibiotics in prophylaxis
for TRUS biopsies.
In conclusion, our preliminary results demonstrate that the
addition of IM gentamicin (80 mg) is beneﬁcial in improving theefﬁcacy of ﬂuoroquinolones and reducing the post-TRUS biopsy
infection rate. Gentamicin is relatively inexpensive and readily
available in daily practice with good compliance for patient use,
except in patients with marked renal function impairment. Once a
post-TRUS biopsy-related infection is noted, third- or fourth-
generation cephalosporins, carbapenem, or piperacillin/tazo-
bactam are the recommended empirical treatments.
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